Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivo
8.5
来源：
Nature
发布时间：
2025-08-27 23:44
摘要：
HB2198 is a novel bispecific antibody targeting CD19 and CD20, developed using GEM-DIMER™ technology. It exhibits enhanced effector functions and demonstrates robust B cell depletion in vitro and in vivo, with over 99% depletion in cynomolgus monkeys within days. The study highlights its potential as a treatment for autoimmune diseases and hematological malignancies, addressing the unmet need for more effective B cell-depleting therapies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
HB2198 demonstrated robust depletion of human B cells that exceeded the levels observed with comparator anti-CD19 or anti-CD20 IgG1 antibodies.
In cynomolgus monkeys, HB2198 administration resulted in > 99% depletion of circulating B cells within 1–3 days.
The dual Fc domains of HB2198 result in considerably higher avidity for the immobilized FcγR than conventional antibodies.
真实性检查
否
AI评分总结
HB2198 is a novel bispecific antibody targeting CD19 and CD20, developed using GEM-DIMER™ technology. It exhibits enhanced effector functions and demonstrates robust B cell depletion in vitro and in vivo, with over 99% depletion in cynomolgus monkeys within days. The study highlights its potential as a treatment for autoimmune diseases and hematological malignancies, addressing the unmet need for more effective B cell-depleting therapies.